Stukenborg Jan-Bernd, Wyns Christine
NORDFERTIL Research Lab Stockholm, Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet and Karolinska University Hospital, Solna, Sweden.
Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Ecancermedicalscience. 2020 Feb 27;14:1016. doi: 10.3332/ecancer.2020.1016. eCollection 2020.
Genetic parenthood following cancer therapy is considered to be a major factor of quality of life. Given the rising proportion of patients surviving cancer due to improved therapeutic protocols, it is an issue of growing importance. Hence, the efforts to preserve fertility have motivated researchers to develop options for the paediatric population facing fertility-threatening cancer therapies. In prepubertal boys who do not yet produce sperm, cryo-banking of testicular tissue containing spermatogonial stem cells (SSCs) is the only viable option for future fertility preservation. While proposed in a number of clinics worldwide, however, this strategy remains still experimental. Transplanting the SSCs, or testicular tissue containing SSCs, back to the cured patient appears the most promising strategy. However, experiments performed with human testicular tissue in mice models reveal spermatogonial loss after transplantation, indicating the need for further optimisation of the transplantation procedure. The approach further poses the risk of reintroducing tumour cells back to the patient. In cases of haematological and blood-metastasising malignancies, generation of sperm combined with assisted reproductive technologies (ART), is the only possibility, avoiding reintroducing cancer cells. Although xenotransplantation would allow to recover sperm cells for ART being thus on the safe side with regard to cancer cells, the risk of infections with xeno-microbiological agents makes this option incompatible with clinical application. So far, offspring from matured sperm has only been achieved in mice. While human haploid germ cells, showing specific morphological features, expression of post-meiotic markers, as well as DNA and chromosome content, as well as fertilisation and development capacity, have been obtained by culturing spermatogonia or immature testicular tissue, the functionality of these cells still needs to be demonstrated. Despite the promising results obtained in recent years, further research is urgently warranted to establish a clinical tool offering these boys a fertility restoration option in the future. This mini-review will focus on current achievements and future challenges of fertility preservation in young boys and underscore the next steps required to translate experimental strategies into clinical practice.
癌症治疗后的遗传亲权被认为是生活质量的一个主要因素。鉴于由于治疗方案的改进,癌症存活患者的比例不断上升,这一问题变得越来越重要。因此,为保留生育能力所做的努力促使研究人员为面临威胁生育能力的癌症治疗的儿科人群开发相关选择。对于尚未产生精子的青春期前男孩,冷冻保存含有精原干细胞(SSCs)的睾丸组织是未来保留生育能力的唯一可行选择。然而,尽管全球多家诊所都提出了这一策略,但它仍处于实验阶段。将SSCs或含有SSCs的睾丸组织移植回治愈的患者体内似乎是最有前景的策略。然而,在小鼠模型中用人睾丸组织进行的实验显示移植后精原细胞丢失,这表明需要进一步优化移植程序。这种方法还存在将肿瘤细胞重新引入患者体内的风险。对于血液学和血行转移恶性肿瘤病例,结合辅助生殖技术(ART)产生精子是唯一的可能性,可避免重新引入癌细胞。尽管异种移植可以回收用于ART的精子细胞,从而在癌细胞方面处于安全状态,但感染异种微生物制剂的风险使得这种选择不符合临床应用。到目前为止,仅在小鼠中实现了由成熟精子产生后代。虽然通过培养精原细胞或未成熟睾丸组织获得了具有特定形态特征、减数分裂后标记物表达、DNA和染色体含量以及受精和发育能力的人类单倍体生殖细胞,但这些细胞的功能仍需证明。尽管近年来取得了令人鼓舞的结果,但迫切需要进一步研究,以建立一种临床工具,为这些男孩提供未来恢复生育能力的选择。本综述将聚焦于年轻男孩生育力保存的当前成就和未来挑战,并强调将实验策略转化为临床实践所需的后续步骤。